D. E. Shaw & Co., Inc. Halozyme Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 619,562 shares of HALO stock, worth $33.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
619,562
Previous 831,414
25.48%
Holding current value
$33.7 Million
Previous $39.7 Million
0.54%
% of portfolio
0.04%
Previous 0.03%
Shares
31 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$958 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$698 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$329 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$212 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$200 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.57B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...